MiNK Therapeutics (INKT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on MiNK Therapeutics (INKT) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.15 of bullish evidence against -0.43 bearish.

MiNK Therapeutics last closed at $12.20, -1.93% on the session.

Against the IVW growth benchmark the position is -2.85% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

16 graded predictions for INKT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks MiNK Therapeutics in the 95th percentile on return on equity, where 100 is best.

MiNK Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $63.48M.

StockMap tracks MiNK Therapeutics as the 275th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite MiNK Therapeutics ranks 289th of 344 in the group, against a group median of -0.21.